Global Key Solutions Corp. Secures Undisclosed Pre-Seed Funding for Data-Driven Technology Development
In regulated industries, information is never the problem. Interpretation is. Every FDA Form 483, every Warning Letter, every citation already exists in public view, sitting there like loose keys on...
In regulated industries, information is never the problem. Interpretation is. Every FDA Form 483, every Warning Letter, every citation already exists in public view, sitting there like loose keys on a cluttered desk. Global Key Solutions Corp., founded in 2023, looked at that mess and asked a sharper question. What if those keys actually unlocked foresight instead of panic? What if regulatory data stopped being archival and started behaving like intelligence?
Built between Brooklyn, New York and Scranton, Pennsylvania at the Scranton Enterprise Center, Global Key Solutions is a pre-revenue company with a very specific obsession. Turn FDA regulatory history into something operators can use before inspectors show up. The company’s platform, KeyPedia, aggregates more than 12,000 FDA regulatory records and profiles over 1,500 professionals, updating daily, mapping patterns most teams only recognize after the damage is done. This is not compliance theater. This is preparation with receipts.
The company was co-founded by George Kwiecinski, Chief Executive Officer, and Zephaniah Christopher C. Odidika, Chief Technology Officer, both engineering graduates of The Cooper Union for the Advancement of Science and Art. They did not come from marketing decks or consulting slides. They came out of data, research, and firsthand exposure to how fragmented regulatory insight slows real decision making. Their insight was simple and uncomfortable. Life sciences teams are drowning in documents and starving for clarity.
In January 2026, Global Key Solutions announced a pre-seed investment of undisclosed amount from Krieger Capital, led by Managing Partner and President Joseph C. Morwald. The capital signals confidence, but the subtext matters more. Krieger Capital invests where complexity is unavoidable and precision pays off. This funding strengthens an ongoing seed effort and fuels deeper product development, expanded datasets, and more advanced analytics across pharmaceutical, medical device, biotech, CMO, and FDA regulated engineering environments.
KeyPedia does not promise miracles. It does something more dangerous. It shows trends. It connects observations to outcomes. It turns yesterday’s enforcement actions into tomorrow’s preparation. Backed by advisors like former FDA investigator Daniel Barreto, life sciences executive Erika Hanley Onken, and quality leader Dr. Ligia Zubik, the company sits at the intersection of regulatory memory and operational muscle.
In an industry where one missed detail can stall a plant or stall a career, Global Key Solutions is not chasing headlines. It is building the keys companies wish they had reached for sooner.